Rocío Jiménez-Guerrero

Dr. Rocío Jiménez-Guerrero

Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41012 Seville, Spain.
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2020 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
JGJ. Gasca
J. Gasca
MFM. L. Flores
M. L. Flores
RJRocío Jiménez-Guerrero
Rocío Jiménez-Guerrero
MSMaria E Saez
Maria E Saez
Isabel BarraganIsabel Barragan
Isabel Barragan
MJMiguel Japón
Miguel Japón
Epithelial–mesenchymal transition (EMT) has recently been associated with tumor progression, metastasis, and chemotherapy resistance in several tumor types. We performed a differential gene expression analysis comparing paclitaxel-resistant vs. paclitaxel-sensitive breast cancer cells that showed the upregulation ofEDIL3(EGF Like Repeats and Discoidin I Like Domains Protein 3). This gene codifies an extracellular matrix protein that has been identified as a novel regulator of EMT, so we studied its role in tumor progression and paclitaxel response. Our results demonstrated that EDIL3 expression levels were increased in paclitaxel-resistant breast and prostate cancer cells, and in subsets of high-grade breast and prostate tumors. Moreover, we observed that EDIL3 modulated the expression of EMT markers and this was impaired by cilengitide, which blocks the EDIL3–integrin αVβ3interaction. EDIL3 knockdown reverted EMT and sensitized cells to paclitaxel. In contrast, EDIL3 overexpression or the culture of cells in the presence of EDIL3-enriched medium induced EMT and paclitaxel resistance. Adding cilengitide resensitized these cells to paclitaxel treatment. In summary, EDIL3 may contribute to EMT and paclitaxel resistance through autocrine or paracrine signaling in cancer cells. Blockade of EDIL3–integrin αVβ3interaction by cilengitide restores sensitivity to paclitaxel and reverts EMT in paclitaxel-resistant cancer cells. Combinations of cilengitide and taxanes could be beneficial in the treatment of subsets of breast and prostate cancers.

Verified
Journal Article
Open access
PDF file
RJRocío Jiménez-Guerrero
Rocío Jiménez-Guerrero
ABAlejandro Belmonte-Fernández
Alejandro Belmonte-Fernández
MFM. Luz Flores
M. Luz Flores
MGMónica González-Moreno
Mónica González-Moreno
BPBegoña Pérez-Valderrama
Begoña Pérez-Valderrama
CSCarmen Sáez
Carmen Sáez
The Wnt/β-catenin pathway plays an important role in tumor progression and chemotherapy resistance and seems to be essential for the maintenance of cancer stem cells (CSC) in several tumor types. However, the interplay of these factors has not been fully addressed in bladder cancer. Here, our goal was to analyze the role of the Wnt/β-catenin pathway in paclitaxel resistance and to study the therapeutic efficacy of its inhibition in bladder cancer cells, as well as to determine its influence in the maintenance of the CSC-like phenotype in bladder cancer. Our results show that paclitaxel-resistant HT1197 cells have hyperactivation of the Wnt/β-catenin pathway and increased CSC-like properties compared with paclitaxel-sensitive 5637 cells. Paclitaxel sensitivity diminishes in 5637 cells after β-catenin overexpression or when they are grown as tumorspheres, enriched for the CSC-like phenotype. Additionally, downregulation of β-catenin or inhibition with XAV939 sensitizes HT1197 cells to paclitaxel. Moreover, a subset of muscle-invasive bladder carcinomas shows aberrant expression of β-catenin that associates with positive expression of the CSC marker ALDH1A1. In conclusion, we demonstrate that Wnt/β-catenin signaling contributes to paclitaxel resistance in bladder cancer cells with CSC-like properties.

5 December 2018 in Cancers
Verified
Journal Article
Open access
PDF file
RJRocío Jiménez-Guerrero
Rocío Jiménez-Guerrero
JGJessica Gasca
Jessica Gasca
MFM. Luz Flores
M. Luz Flores
BPBegoña Pérez-Valderrama
Begoña Pérez-Valderrama
CTCristina Tejera-Parrado
Cristina Tejera-Parrado
CSCarmen Sáez
Carmen Sáez
Paclitaxel is a treatment option for advanced or metastatic bladder cancer after the failure of first-line cisplatin and gemcitabine, although resistance limits its clinical benefits. Mcl-1 is an anti-apoptotic protein that promotes resistance to paclitaxel in different tumors. Obatoclax, a BH3 mimetic of the Bcl-2 family of proteins, antagonizes Mcl-1 and hence may reverse paclitaxel resistance in Mcl-1-overexpressing tumors. In this study, paclitaxel-sensitive 5637 and -resistant HT1197 bladder cancer cells were treated with paclitaxel, obatoclax, or combinations of both. Apoptosis, cell cycle, and autophagy were measured by Western blot, flow cytometry, and fluorescence microscopy. Moreover, Mcl-1 expression was analyzed by immunohistochemistry in bladder carcinoma tissues. Our results confirmed that paclitaxel alone induced Mcl-1 downregulation and apoptosis in 5637, but not in HT1197 cells; however, combinations of obatoclax and paclitaxel sensitized HT1197 cells to the treatment. In obatoclax-treated 5637 and obatoclax + paclitaxel-treated HT1197 cells, the blockade of the autophagic flux correlated with apoptosis and was associated with caspase-dependent cleavage of beclin-1. Obatoclax alone delayed the cell cycle in 5637, but not in HT1197 cells, whereas combinations of both retarded the cell cycle and reduced mitotic slippage. In conclusion, obatoclax sensitizes HT1197 cells to paclitaxel-induced apoptosis through the blockade of the autophagic flux and effects on the cell cycle. Furthermore, Mcl-1 is overexpressed in many invasive bladder carcinomas, and it is related to tumor progression, so Mcl-1 expression may be of predictive value in bladder cancer.

6 October 2026 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MGMónica González-Moreno
Mónica González-Moreno
RJRocío Jiménez-Guerrero
Rocío Jiménez-Guerrero
BPBegoña Pérez-Valderrama
Begoña Pérez-Valderrama
RMRafael Antonio Medina-Lopez
Rafael Antonio Medina-Lopez
IRInés Rivero-Belenchón
Inés Rivero-Belenchón
CSCarmen Sáez
Carmen Sáez
Muscle-invasive bladder cancer is most often treated with radical surgery and perioperative cisplatin-based chemotherapy, this represents a challenge for p